庄文卓

发布时间:2024-01-29浏览次数:1521

1.淋巴系统肿瘤非编码RNA表观遗传学研究。

2.淋巴系统肿瘤药物的分子靶点及药物协同作用研究。

3.探寻淋巴系统肿瘤分层诊断、预后评估的分子标志物,为实现淋巴系统肿瘤的个体化诊断和精准治疗提供策略。


以第一或通讯作者发表文章:


1.    Han H, Fan G, Song S, Jiang Y, Qian C, Zhang W, Su Q, Xue X, Zhuang W (corresponding author), Li B. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL. Blood. 2021 Mar 25;137(12):1603-1614. 

2.      Song S, Fan G, Li Q, Su Q, Zhang X, Xue X, Wang Z, Qian C, Jin Z, Li B, Zhuang W (corresponding author). IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma. Oncogene. 2021 Sep;40(35):5393-5402. 

3.    Song S, Zhang J, Su Q, Zhang W, Jiang Y, Fan G, Qian C, Li B, Zhuang W (corresponding co-author). Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia. Br J Cancer.2021 May;124(11):1843-1853. 

4.    Xu H, Han H, Song S, Yi N, Qian C, Qiu Y, Zhou W, Hong Y, Zhuang W, Li Z, Li B, Zhuang W(corresponding author). Exosome-Transmitted PSMA3 and PSMA3-AS1 Promotes Proteasome Inhibitors Resistance in Multiple Myeloma. Clin Cancer Res. 2019 Mar 15;25(6):1923-1935. 

5.    Li B, Xu H, Han H, Song S, Zhang X, Ouyang L, Qian C, Hong Y, Qiu Y, Zhou W, Huang M*, Zhuang W*. Exosome-Mediated Transfer of lncRUNX2-AS1 from Multiple Myeloma Cells to MSCs Contributes to Osteogenesis. Oncogene. 2018 Oct;37(41):5508-5519. 

6.    Li B, Han H, Song S, Fan G, Xu H, Zhou W, Qiu Y, Qian C, Wang Y, Yuan Z, Zhang Y*, Zhuang W*.HOXC10 Regulates Osteogenesis of Mesenchymal Stromal Cells through Interaction with its Natural Antisense Transcript lncHOXC-AS3.Stem Cells.2019 Feb;37(2):247-256. 

7.     Gu J, Song S, Han H, Xu H, Fan G, Qian C, Qiu Y, Zhou W, Zhuang W*, Li B*.The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma. Mol Pharm. 2018 Nov 5;15(11):5387-5396. 

8.     Shi J, Song S, Han H, Xu H, Huang M, Qian C, Zhang X, Ouyang L, Hong Y, Zhuang W*, Li B*. Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma. Mol Pharm. 2018 Sep4;15(9):4139-4147. 

9.     Zhang X, Li B, Han H, Song S, Xu H, Yi Z, Hong Y, Zhuang W*, Yi N*. Pathway-Structured Predictive Modeling for Multi-Level Drug Response in Multiple Myeloma. Bioinformatics. 2018 Nov 1;34(21):3609-3615. 

10.   Zhang X, Li B, Han H, Song S, Xu H, Hong Y, Yi N*, Zhuang W*. Predicting Multi-Level Drug Response with Gene Expression Profile in Multiple Myeloma Using Hierarchical Ordinal Regression. BMC Cancer. 2018 May 10;18(1):551.

11.   Zhuang W, Ge X, Yang S, Huang M, Zhuang W, Chen P, Zhang X, Qu J, Li B*.Upregulation of lncRNA MEG3 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells from Multiple Myeloma Patients by Targeting BMP4 Transcription. Stem Cells. 2015 Jun;33(6):1985-97. 

12.   Li B, Chen P, Qu J, Shi L, Zhuang W, Fu J, Li J, Zhang X, Sun Y, Zhuang W*. Activation of LTBP3 Gene by a Long Noncoding RNA (lncRNA) MALAT1 Transcript in Mesenchymal Stem cells from Multiple Myeloma. J Biol Chem. 2014 Oct 17;289(42):29365-75.